Ambeed.cn

首页 / / / / Bruceine D

鸦胆子苦素D /Bruceine D {[allProObj[0].p_purity_real_show]}

货号:A313823 同义名: 鸦胆子素D

Bruceine D 是一种 Notch 抑制剂,具有抗癌活性,可在多个人类癌细胞系中诱导凋亡。Bruceine D 对 D. intermedius 显示出强效的杀虫活性,其 EC50 值为 0.57 mg/L。

Bruceine D 化学结构 CAS号:21499-66-1
Bruceine D 化学结构
CAS号:21499-66-1
Bruceine D 3D分子结构
CAS号:21499-66-1
Bruceine D 化学结构 CAS号:21499-66-1
Bruceine D 3D分子结构 CAS号:21499-66-1
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Bruceine D 纯度/质量文件 产品仅供科研

货号:A313823 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Cell, 2024, 101755. Ambeed. [ A399663 ]
EMBO J., 2024. Ambeed. [ A295334 ]
JMC, 2024, 67(20): 18265-18289. Ambeed. [ A538667 , A341145 , A117430 , A172297 ]
JMC, 2024. Ambeed. [ A210558 , A1518164 ]
Cell Death Discov., 2024, 10, 436. Ambeed. [ A384235 ]
更多 >

Bruceine D 生物活性

描述 Bruceine D is an effective botanical insect antifeedant with outstanding systemic properties, causing potent pest growth inhibitory activity[3]. Bruceine D is a Notch inhibitor with anti-cancer activity and induces apoptosis in several human cancer cells. BD significantly inhibited liver tumor growth and enhanced the therapeutic effects of sorafenib in various murine HCC (Hepatocellular carcinoma) models[4]. Bruceine D exhibited potent cytotoxicity to K562 cells with IC50 of 6.37 ± 0.39 μM. In addition, bruceine D inhibited the phosphorylation of AKT and ERK. It's indicative that the potent anticancer activity of bruceine D be related to MAPK and PI3K pathways[5]. Bruceine D markedly inhibited the proliferation of wild‑type NSCLC (non‑small‑cell lung cancer) cells and epidermal growth factor receptor‑mutant cells in a dose‑ and time‑dependent manner, and significantly decreased the colony‑forming ability and migration of A549 cells[6].

Bruceine D 参考文献

[1]Liu L, Lin ZX, et al. Involvement of the mitochondrial pathway in bruceine D-induced apoptosis in Capan-2 human pancreatic adenocarcinoma cells. Int J Mol Med. 2012 Jul;30(1):93-9.

[2]Wang Y, Wu ZF, et al. In vivo anthelmintic activity of bruceine A and bruceine D from Brucea javanica against Dactylogyrus intermedius (Monogenea) in goldfish (Carassius auratus). Vet Parasitol. 2011 Apr 19;177(1-2):127-33.

[3]Mao G, Tian Y, Sun Z, Ou J, Xu H. Bruceine D Isolated from Brucea Javanica (L.) Merr. as a Systemic Feeding Deterrent for Three Major Lepidopteran Pests. J Agric Food Chem. 2019;67(15):4232-4239

[4]Cheng Z, Yuan X, Qu Y, et al. Bruceine D inhibits hepatocellular carcinoma growth by targeting β-catenin/jagged1 pathways. Cancer Lett. 2017;403:195-205

[5]Zhang JY, Lin MT, Tung HY, et al. Bruceine D induces apoptosis in human chronic myeloid leukemia K562 cells via mitochondrial pathway. Am J Cancer Res. 2016;6(4):819-826. Published 2016 Mar 15

[6]Xie JH, Lai ZQ, Zheng XH, et al. Apoptosis induced by bruceine D in human non‑small‑cell lung cancer cells involves mitochondrial ROS‑mediated death signaling. Int J Mol Med. 2019;44(6):2015-2026

Bruceine D 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.44mL

0.49mL

0.24mL

12.18mL

2.44mL

1.22mL

24.37mL

4.87mL

2.44mL

Bruceine D 技术信息

CAS号21499-66-1
分子式C20H26O9
分子量 410.415
别名 鸦胆子素D
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Sealed in dry,2-8°C

溶解度

DMSO: 105 mg/mL(255.84 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

H2O: 5 mg/mL(12.18 mM),配合低频超声,并水浴加热至45℃助溶

动物实验配方
Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。